🧵 New 2026 NICE Update on Initial Drug Therapy in Type 2 Diabetes Detailed Thread 1️⃣ Big Shift in Philosophy This is no longer just about lowering HbA1c. The new guidance prioritises: • Cardiovascular protection • Renal protection • Individualised treatment • Early combination therapy Glucose control is important but outcomes matter more. 2️⃣ First-Line Therapy (No Major Comorbidities) For most adults: ✅ Modified-release metformin PLUS ✅ An SGLT-2 inhibitor If metformin cannot be used → start SGLT-2 inhibitor alone. ➡️ This is a major shift from traditional “metformin first, add later.” 3️⃣ Why SGLT-2 So Early? Because evidence now strongly supports: • Reduction in heart failure hospitalization • Slowing CKD progression • Cardiovascular mortality benefit • Weight reduction • Low hypoglycaemia risk This class is now foundational therapy. 4️⃣ If the Patient Has Heart Failure Start immediately: ✅ Metformin ✅ SGLT-2 inhibitor If metformin contraindicated → SGLT-2 alone. HF benefit drives this decision independent of HbA1c. 5️⃣ If Atherosclerotic CVD Is Present Initial therapy can include: ✅ Metformin ✅ SGLT-2 inhibitor ✅ Subcutaneous semaglutide (GLP-1 RA) If Yes 👉🏻 GLP-1 RA can now be started upfront in ASCVD. This reflects strong CV outcome trial data. 6️⃣ Early-Onset Type 2 Diabetes (Younger patients, aggressive phenotype) Start: ✅ Metformin ✅ SGLT-2 inhibitor Consider adding: • GLP-1 receptor agonist • Tirzepatide This group often needs earlier intensification. 7️⃣ Obesity + Type 2 Diabetes Initial therapy: ✅ Metformin ✅ SGLT-2 inhibitor Weight-neutral or weight-reducing strategies are preferred. Avoid agents that promote weight gain unless necessary. 8️⃣ Chronic Kidney Disease (CKD) Treatment depends on eGFR: 🔹 eGFR >30 → Metformin + SGLT-2 🔹 eGFR 20–30 → Dapagliflozin or Empagliflozin + DPP-4 inhibitor 🔹 eGFR <20 → Consider DPP-4 inhibitor If DPP-4 not suitable → consider pioglitazone or insulin. Renal protection is central in this update. 9️⃣ Frailty Be cautious. Offer: ✅ Metformin Consider SGLT-2 only if risk of: • Hypotension • Dehydration • Falls If risk is high → DPP-4 inhibitor may be safer. Individualisation is critical here. 🔟 What’s Clearly De-emphasised? Sulfonylureas are no longer early go-to drugs. Reasons: • Hypoglycaemia risk • Weight gain • No cardiovascular benefit They are now secondary options. 1️⃣1️⃣ Key Takeaway The 2026 update moves us from: “Glucose-centric diabetes care” ➡️ to “Cardio-renal-metabolic protection from day one.” Early combination therapy is now the norm, not the exception. 1️⃣2️⃣ Practical Clinical Message When starting treatment in Type 2 Diabetes, now ask: • Does this patient have HF? • ASCVD? • CKD? • Obesity? • Frailty? The comorbidity determines the drug choice not just HbA1c. nice.org.uk/guidance/ng28/ch… #MedTwitter #MedX